Earnings Summary

Gilead Sciences Inc.’s revenue fell -99.79% since last year same period to $13.6Mn in the Q1 2023. On a quarterly growth basis, Gilead Sciences Inc. has generated -99.82% fall in its revenue since last 3-months.

Gilead Sciences Inc.’s net profit fell -138.95% since last year same period to $-7.4Mn in the Q1 2023. On a quarterly growth basis, Gilead Sciences Inc. has generated -100.45% fall in its net profits since last 3-months.

Gilead Sciences Inc.’s net profit margin fell -18972.29% since last year same period to -54.41% in the Q1 2023. On a quarterly growth basis, Gilead Sciences Inc. has generated -345.15% fall in its net profit margins since last 3-months.

Gilead Sciences Inc.’s price-to-earnings ratio after this Q1 2023 earnings stands at 17.44.

Gilead Sciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.49 - a 4.2% jump from last quarter’s estimates.

Gilead Sciences Inc.’s earning per share (EPS) estimates for the current year stand at 1.49.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Gilead Sciences Inc.’s return on assets (ROA) stands at 0.1.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Gilead Sciences Inc.’s return on equity (ROE) stands at 0.27.

Gilead Sciences Inc. declared 0.75 dividend per share during the earnings announcement for Q1 2023.